397 related articles for article (PubMed ID: 14966099)
1. Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature.
Liede A; Karlan BY; Narod SA
J Clin Oncol; 2004 Feb; 22(4):735-42. PubMed ID: 14966099
[TBL] [Abstract][Full Text] [Related]
2. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
[TBL] [Abstract][Full Text] [Related]
3. Counseling for male BRCA mutation carriers: a review.
Mohamad HB; Apffelstaedt JP
Breast; 2008 Oct; 17(5):441-50. PubMed ID: 18657973
[TBL] [Abstract][Full Text] [Related]
4. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada.
Risch HA; McLaughlin JR; Cole DE; Rosen B; Bradley L; Fan I; Tang J; Li S; Zhang S; Shaw PA; Narod SA
J Natl Cancer Inst; 2006 Dec; 98(23):1694-706. PubMed ID: 17148771
[TBL] [Abstract][Full Text] [Related]
5. Familial clustering of site-specific cancer risks associated with BRCA1 and BRCA2 mutations in the Ashkenazi Jewish population.
Simchoni S; Friedman E; Kaufman B; Gershoni-Baruch R; Orr-Urtreger A; Kedar-Barnes I; Shiri-Sverdlov R; Dagan E; Tsabari S; Shohat M; Catane R; King MC; Lahad A; Levy-Lahad E
Proc Natl Acad Sci U S A; 2006 Mar; 103(10):3770-4. PubMed ID: 16537453
[TBL] [Abstract][Full Text] [Related]
6. The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain.
Milne RL; Osorio A; Cajal TR; Vega A; Llort G; de la Hoya M; Díez O; Alonso MC; Lazaro C; Blanco I; Sánchez-de-Abajo A; Caldés T; Blanco A; Graña B; Durán M; Velasco E; Chirivella I; Cardeñosa EE; Tejada MI; Beristain E; Miramar MD; Calvo MT; Martínez E; Guillén C; Salazar R; San Román C; Antoniou AC; Urioste M; Benítez J
Clin Cancer Res; 2008 May; 14(9):2861-9. PubMed ID: 18451254
[TBL] [Abstract][Full Text] [Related]
7. Risk factors for carcinoma of the fallopian tube in women with and without a germline BRCA mutation.
Vicus D; Finch A; Rosen B; Fan I; Bradley L; Cass I; Sun P; Karlan B; McLaughlin J; Narod SA;
Gynecol Oncol; 2010 Aug; 118(2):155-9. PubMed ID: 20452659
[TBL] [Abstract][Full Text] [Related]
8. Use of expression data and the CGEMS genome-wide breast cancer association study to identify genes that may modify risk in BRCA1/2 mutation carriers.
Walker LC; Waddell N; Ten Haaf A; ; Grimmond S; Spurdle AB
Breast Cancer Res Treat; 2008 Nov; 112(2):229-36. PubMed ID: 18095154
[TBL] [Abstract][Full Text] [Related]
9. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.
Antoniou AC; Durocher F; Smith P; Simard J; Easton DF;
Breast Cancer Res; 2006; 8(1):R3. PubMed ID: 16417652
[TBL] [Abstract][Full Text] [Related]
10. Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
Jernström H; Lubinski J; Lynch HT; Ghadirian P; Neuhausen S; Isaacs C; Weber BL; Horsman D; Rosen B; Foulkes WD; Friedman E; Gershoni-Baruch R; Ainsworth P; Daly M; Garber J; Olsson H; Sun P; Narod SA
J Natl Cancer Inst; 2004 Jul; 96(14):1094-8. PubMed ID: 15265971
[TBL] [Abstract][Full Text] [Related]
11. BRCA1 and BRCA2 mutation prevalence and clinical characteristics of a population-based series of ovarian cancer cases from Denmark.
Soegaard M; Kjaer SK; Cox M; Wozniak E; Høgdall E; Høgdall C; Blaakaer J; Jacobs IJ; Gayther SA; Ramus SJ
Clin Cancer Res; 2008 Jun; 14(12):3761-7. PubMed ID: 18559594
[TBL] [Abstract][Full Text] [Related]
12. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
[TBL] [Abstract][Full Text] [Related]
13. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.
Rebbeck TR; Friebel T; Lynch HT; Neuhausen SL; van 't Veer L; Garber JE; Evans GR; Narod SA; Isaacs C; Matloff E; Daly MB; Olopade OI; Weber BL
J Clin Oncol; 2004 Mar; 22(6):1055-62. PubMed ID: 14981104
[TBL] [Abstract][Full Text] [Related]
14. Parity and breast cancer risk among BRCA1 and BRCA2 mutation carriers.
Antoniou AC; Shenton A; Maher ER; Watson E; Woodward E; Lalloo F; Easton DF; Evans DG
Breast Cancer Res; 2006; 8(6):R72. PubMed ID: 17187672
[TBL] [Abstract][Full Text] [Related]
15. Loss of heterozygosity at the BRCA2 locus detected by multiplex ligation-dependent probe amplification is common in prostate cancers from men with a germline BRCA2 mutation.
Willems AJ; Dawson SJ; Samaratunga H; De Luca A; Antill YC; Hopper JL; Thorne HJ;
Clin Cancer Res; 2008 May; 14(10):2953-61. PubMed ID: 18445692
[TBL] [Abstract][Full Text] [Related]
16. BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives.
Lalloo F; Varley J; Moran A; Ellis D; O'dair L; Pharoah P; Antoniou A; Hartley R; Shenton A; Seal S; Bulman B; Howell A; Evans DG
Eur J Cancer; 2006 May; 42(8):1143-50. PubMed ID: 16644204
[TBL] [Abstract][Full Text] [Related]
17. Age at menarche and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
Kotsopoulos J; Lubinski J; Lynch HT; Neuhausen SL; Ghadirian P; Isaacs C; Weber B; Kim-Sing C; Foulkes WD; Gershoni-Baruch R; Ainsworth P; Friedman E; Daly M; Garber JE; Karlan B; Olopade OI; Tung N; Saal HM; Eisen A; Osborne M; Olsson H; Gilchrist D; Sun P; Narod SA
Cancer Causes Control; 2005 Aug; 16(6):667-74. PubMed ID: 16049805
[TBL] [Abstract][Full Text] [Related]
18. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.
Metcalfe K; Lynch HT; Ghadirian P; Tung N; Olivotto I; Warner E; Olopade OI; Eisen A; Weber B; McLennan J; Sun P; Foulkes WD; Narod SA
J Clin Oncol; 2004 Jun; 22(12):2328-35. PubMed ID: 15197194
[TBL] [Abstract][Full Text] [Related]
19. Coinheritance of BRCA1 and BRCA2 mutations with Fanconi anemia and Bloom syndrome mutations in Ashkenazi Jewish population: possible role in risk modification for cancer development.
Koren-Michowitz M; Friedman E; Gershoni-Baruch R; Brok-Simoni F; Patael Y; Rechavi G; Amariglio N
Am J Hematol; 2005 Mar; 78(3):203-6. PubMed ID: 15726604
[TBL] [Abstract][Full Text] [Related]
20. Incidence of BRCA1 and BRCA2 mutations in 54 Chilean families with breast/ovarian cancer, genotype-phenotype correlations.
Gallardo M; Silva A; Rubio L; Alvarez C; Torrealba C; Salinas M; Tapia T; Faundez P; Palma L; Riccio ME; Paredes H; Rodriguez M; Cruz A; Rousseau C; King MC; Camus M; Alvarez M; Carvallo P
Breast Cancer Res Treat; 2006 Jan; 95(1):81-7. PubMed ID: 16261400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
